Phase II study of the combination carboplatin and paclitaxel in patients with ovarian cancer

Annals of Oncology

Volumn 8, Issue 4, 1997, Pages 351-354

  Ten Bokkel Huinink, W W ^a,b   Van Warmerdam, L J C ^a   Helmerhorst, T J ^a   Schaefers, M C W ^a   Beijnen, J H ^a   Rodenhuis, S ^a  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Carboplatin; Ovarian cancer; Paclitaxel; Phase II

Indexed keywords

CARBOPLATIN; PACLITAXEL;

ADULT; AGED; ARTICLE; BONE PAIN; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MYALGIA; NEUROTOXICITY; OVARY CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PACLITAXEL;

EID: 0031009243     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008219618331     Document Type: Article

References (17)

1. Wagstaff AJ, Ward A, Benfield P et al. Carboplatin, a preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of cancer. Drugs 1989; 37: 162-90.
2. Vermorken JB, ten Bokkel Huinink WW, Eisenhower EA et al. Carboplatin versus cisplatin. Ann Oncol 1993; 4 (Suppl 4): S41-8.
3. Jodrell DI, Egorin MJ, Canetta RM et al. Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol 1992; 10: 520-8.
4. Spencer CM, Faulds D. Paclitaxel: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatments of cancer. Drugs 1994; 48: 794-847.
5. Rowinsky EK. Clinical pharmacology of taxol. J Natl Cancer Inst 1993; 15: 25-37.
6. Huizing MT, Misser VH, Pieters RC et al. Taxanes: A new class of antitumor agents. Cancer Invest 1995; 13: 381-404.
7. McGuire WP, Hoskins WJ, Brady PR et al. A Phase III trial comparing cisplatin/cytoxan and cisplatin/taxol in advanced ovarian cancer. N Engl J Med 1996; 334: 1-6.
8. Thigpen T, Vance R, Puneky L, Khansur T. Chemotherapy in advanced ovarian carcinoma: Current standards of care based on randomized trials. Gynecol Oncol 1994; 55: S97-S107.
9. Rowinsky EK, Chaudhry V, Forastiere AA et al. Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: Neuromuscular toxicity is dose-limiting. J Clin Oncol 1993; 11: 2010-20.
10. Huizing MT, Van Warmerdam LJC, Rosing H et al. Phase I and pharmacology study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancer. J Clin Oncol 1996; in press.
11. Langer CJ, Leighton JC, Comis R et al. Paclitaxel by 24- or 1-hour infusion in combination with carboplatin in advanced non-small cell lung cancer: The Fox Chase cancer center experience. Semin Oncol 1995; 22: 18-29.
12. Belani CP, Aisner J, Hiponia D et al. Paclitaxel and carboplatin with and without filgrastim support in patients with metastatic non-small cell lung cancer. Semin Oncol 1995; 22: 7-12.
13. Israel VK, Zaretsky S, Natale RB. Phase I/II trial of combination carboplatin and taxol in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1994; 13: 351.
14. Johnson DH, Paul DM, Hande KR et al. Paclitaxel and carboplutin for advanced lung cancer: Preliminary results of a vanderbilt university phase II trial. Semin Oncol 1995: 22(4): 30-3.
15. Kearns CM, Belani CP, Erkmen K et al. Reduced platelet toxicity with combination carboplatin & paclitaxel; pharmacodynamic modulation of carboplatin associated thrombocytopenia. Proc Am Assoc Clin Oncol 1995; 14: 170.
16. Shea T, Graham M, Steagall S et al. Multiple cycles of high dose taxol plus carboplatin with G-CSF (filastrim) and peripheral blood progenitor support. Proc Am Soc Clin Oncol 1994; 13: 150.
17. Bookman MA, McGuire WP, Kilpatrick D et al. Carboplatin and paclitaxel in ovarian carcinoma: A phase I study of the gynecologic oncology group. J Clin Oncol 1996; 14: 1895-902.